Patents by Inventor Rudi Beyaert
Rudi Beyaert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11001624Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.Type: GrantFiled: April 4, 2017Date of Patent: May 11, 2021Assignees: VIB VZW, UniversiteitGentInventors: Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
-
Patent number: 10703799Abstract: The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.Type: GrantFiled: December 10, 2013Date of Patent: July 7, 2020Assignees: VIB VZW, Universiteit GentInventors: Rudi Beyaert, Harald Braun, Bart Lambrecht, Hamida Hammad
-
Publication number: 20190127440Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.Type: ApplicationFiled: April 4, 2017Publication date: May 2, 2019Inventors: Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
-
Publication number: 20150315262Abstract: The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.Type: ApplicationFiled: December 10, 2013Publication date: November 5, 2015Inventors: Rudi Beyaert, Harald Braun, Bart Lambrecht, Hamida Hammad
-
Patent number: 8309523Abstract: The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity.Type: GrantFiled: November 20, 2008Date of Patent: November 13, 2012Assignees: VIB VZW, Universiteit Gent, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Rudi Beyaert, Peter Marynen, Thijs Baens, Karen Heyninck
-
Patent number: 7893026Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.Type: GrantFiled: April 11, 2006Date of Patent: February 22, 2011Assignees: VIB VZW, Universiteit Gent, Vrije Universiteit BrusselInventors: Rudi Beyaert, Hilde Revets, Lieven Huang
-
Publication number: 20110021548Abstract: The present invention relates to inhibitors of MALT1 proteolytic and/or autoproteolytic activity. More specifically, it relates to compounds such as, but not limited to peptide derivates such as Z-LSSR-CHO (see SEQ ID NO:1), Z-LSSR-CMK (see SEQ ID NO:1), Z-GASR-CHO (see SEQ ID NO:2), and Z-GASR-CMK (see SEQ ID NO:2), and small compounds such as 5-{[5-(3-chloro-4-methylphenyl)-2-furyl]methylene}-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione and variants thereof, and the use of those compounds for the preparation of a medicament. The invention relates further to a method to screen for inhibitors of the MALT1 proteolytic and/or autoproteolytic activity.Type: ApplicationFiled: November 20, 2008Publication date: January 27, 2011Inventors: Rudi Beyaert, Peter Marynen, Thijs Baens, Karen Heyninck
-
Publication number: 20090023650Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.Type: ApplicationFiled: April 11, 2006Publication date: January 22, 2009Inventors: Rudi Beyaert, Hilde Revets, Lieven Huang
-
Patent number: 7414026Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-?B) activating pathway useful in the treatment of NF-?B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I?B.Type: GrantFiled: October 8, 2003Date of Patent: August 19, 2008Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZWInventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
-
Patent number: 7122656Abstract: The present invention relates to the field of infection and inflammation and, more specifically, to the field of pathogen-induced nuclear factor kappa B activation. More specifically, a novel splice variant of MyD88, (MyD88S), which has been identified encoding a protein that inhibits LPS-induced NF-?B activation. MyD88S is a target to inhibit the phenomenon of endotoxin-tolerance that occurs in sepsis.Type: GrantFiled: July 9, 2004Date of Patent: October 17, 2006Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie VZW, Universiteit GentInventors: Rudi Beyaert, Sophie Janssens
-
Patent number: 7094756Abstract: The present invention relates to the use of the A20-binding inhibitor of NF-?B activation (ABIN), or a functional fragment or variant thereof to protect against TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN.Type: GrantFiled: December 19, 2003Date of Patent: August 22, 2006Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Rudi Beyaert, Ben Wielockx, Sofie Van Huffel, Filip Delaei, Claude Libert
-
Publication number: 20060134737Abstract: The present invention relates to ubiquitinated TNF receptor 2, and the uses thereof. More specifically, the invention relates to the use of TNF receptor 2 ubiquitination to deplete TNF receptor 2 from the cell membrane and cytoplasm, and relocalize it in the insoluble cell fraction. Such relocalization can be used to modulate the signaling activity of the TNF receptor 2 and to treat TNF receptor 2-related diseases. The invention relates further to the use of Smurf 2 to ubiquitinate TNF receptor 2 and to the use of TRAF2 to mediate TNF receptor 2 ubiquitination.Type: ApplicationFiled: December 28, 2005Publication date: June 22, 2006Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Universiteit GentInventors: Rudi Beyaert, Isabelle Carpentier
-
Publication number: 20060019882Abstract: The present invention relates to the use of Yops as caspase inhibitors. More specifically, it relates to the use of YopE and YopT as inhibitors of caspase-1 activity. The inhibitor can be used to treat caspase-1-related pathologies, such as inflammatory diseases and to inhibit caspase-1-related and/or -mediated cell death.Type: ApplicationFiled: July 19, 2005Publication date: January 26, 2006Applicants: Vlaams Interuniversitair Instituut Voor Biotechnologie VZW, Universiteit GentInventors: Rudi Beyaert, Peter Schotte
-
Publication number: 20050181476Abstract: The present invention relates to the field of infection and inflammation and, more specifically, to the field of pathogen-induced nuclear factor kappa B activation. More specifically, a novel splice variant of MyD88, (MyD88S), which has been identified encoding a protein that inhibits LPS-induced NF-?B activation. MyD88S is a target to inhibit the phenomenon of endotoxin-tolerance that occurs in sepsis.Type: ApplicationFiled: July 9, 2004Publication date: August 18, 2005Inventors: Rudi Beyaert, Sophie Janssens
-
Patent number: 6764852Abstract: Two isoforms, p110 and p58 of PITSLRE protein kinase, can be translated from the same p110 (a2-2) mRNA by an internal ribosome entry process. Accordingly, p110 and p58, two proteins with punitive functions, are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 439 C-terminal amino acids that contain the kinase domain. The internal ribosomal entry site (“IRES”) in the polycistronic p110 mRNA is the first IRES completely localized in the coding region of a cellular mRNA. Moreover, it was unexpectedly found that the IRES element is cell cycle regulated. Translation of p58 occurs in the G2/M stage of the cycle.Type: GrantFiled: July 25, 2001Date of Patent: July 20, 2004Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Sigrid Cornelis, Rudi Beyaert
-
Publication number: 20040136978Abstract: The present invention relates to the use of the A20-binding inhibitor of NF-&kgr;B activation (ABIN), or a functional fragment or variant thereof to protect aGalNst TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN.Type: ApplicationFiled: December 19, 2003Publication date: July 15, 2004Inventors: Rudi Beyaert, Ben Wielockx, Sofie Van Huffel, Filip Delaei, Claude Libert
-
Publication number: 20040092430Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-&kgr;B) activating pathway useful in the treatment of NF-&kgr;B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I&kgr;B.Type: ApplicationFiled: October 8, 2003Publication date: May 13, 2004Inventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
-
Patent number: 6673897Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-&kgr;B) activating pathway useful in the treatment of NF-&kgr;B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I&kgr;B.Type: GrantFiled: October 31, 2000Date of Patent: January 6, 2004Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZWInventors: Rudi Beyaert, Karen Heyninck, Walter Fiers
-
Publication number: 20020049181Abstract: Two isoforms, p110 and p58 of PITSLRE protein kinase, can be translated from the same p110 (a2-2) mRNA by an internal ribosome entry process. Accordingly, p110 and p58, two proteins with putative different functions, are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 439 C-terminal amino acids that contain the kinase domain. The internal ribosomal entry site (“IRES”) in the polycistronic p110 mRNA is the first IRES completely localized in the coding region of a cellular mRNA. Moreover, it was unexpectedly found that the IRES element is cell cycle regulated. Translation of p58 occurs in the G2/M stage of the cell cycle.Type: ApplicationFiled: July 25, 2001Publication date: April 25, 2002Inventors: Sigrid Cornelis, Rudi Beyaert